Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 1:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1489–1512 of 3,056 matching trials from the live ClinicalTrials.gov search.
Conditions
Colon Cancer Screening
Interventions
educational video
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
Not listed
Enrollment
270 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Metastatic Colorectal Carcinoma (mCRC), Colorectal Cancer (CRC), Adenomatous Polyposis Coli (APC) Gene Mutation, Catenin Beta-1 (CTNNB1) Gene Mutation
Interventions
Tegavivint
Drug
Lead sponsor
HonorHealth Research Institute
Other
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Scottsdale, Arizona
Conditions
Gastrointestinal Neoplasms
Interventions
Risvutatug Rezetecan
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
12
States / cities
Los Alamitos, California • Los Angeles, California • Santa Monica, California + 8 more
Conditions
Colonic Dysplasia, Adenomatous Polyps, Irritable Bowel Disease
Interventions
confocal endomicroscope, Fluorescein
Device · Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 100 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Diseases of Liver, Colon Carcinoma, Colorectal Carcinoma, Liver Metastases
Interventions
Computed Tomography Scan - 50% Dose Reduction, Computed Tomography Scan - 70% Dose Reduction, Deep Learning Image Reconstruction (DLIR)
Diagnostic Test
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 90 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Houston, Texas
Conditions
Breast Neoplasm, Pancreatic Neoplasm, Lung Neoplasm, Ovarian Neoplasm, Renal Neoplasm
Interventions
TAK-165
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
4
States / cities
Scottsdale, Arizona • San Antonio, Texas
Not listed No phase listed Observational Accepts healthy volunteers

Circulating Tumor DNA Exposure in Peripheral Blood

NCT03517332
Conditions
Colorectal Cancer, Pancreatic Adenocarcinoma, Gastric Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer, Bladder Cancer, Melanoma, Ovarian Cancer, Adrenocortical Cancer, Breast Cancer, Other Cancer
Interventions
Not listed
Lead sponsor
Quantgene Inc.
Industry
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
5
States / cities
Tucson, Arizona • Celebration, Florida • Orlando, Florida + 2 more
Conditions
Colorectal Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, Solid Tumor
Interventions
PT0511, Cetuximab
Drug
Lead sponsor
PAQ Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
5
States / cities
Boston, Massachusetts • San Antonio, Texas • West Valley City, Utah + 1 more
Conditions
Colonic Neoplasms
Interventions
Not listed
Lead sponsor
Metabiomics Corp
Industry
Eligibility
18 Years to 95 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Pain, Colorectal Adenomas, Colorectal Cancer
Interventions
Air Insufflation method., Water Immersion method., Water Exchange method.
Other
Lead sponsor
Presidio Ospedaliero Santa Barbara
Other
Eligibility
18 Years to 85 Years
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Stage I Colorectal Cancer AJCC v8, Stage II Colorectal Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8
Interventions
Educational Intervention, Electronic Health Record Review, Internet-Based Intervention, Patient Navigation, Survey Administration
Other · Behavioral
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Seattle, Washington
Conditions
Colon Cancer, dMMR Colorectal Cancer
Interventions
Dostarlimab
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
2
States / cities
Iowa City, Iowa • Madison, Wisconsin
Conditions
Colorectal Cancer
Interventions
bevacizumab, cetuximab, FOLFIRI regimen, FOLFOX regimen, capecitabine, fluorouracil, irinotecan hydrochloride, leucovorin calcium, mitomycin C, oxaliplatin, therapeutic conventional surgery
Biological · Drug · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years to 120 Years
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Baltimore, Maryland • Winston-Salem, North Carolina
Conditions
Colorectal Neoplasms, Diarrhea
Interventions
PHY906
Drug
Lead sponsor
PhytoCeutica
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
3
States / cities
West Haven, Connecticut • New York, New York • Greenville, South Carolina
Conditions
Colorectal Cancer, Metastases
Interventions
Cetuximab, Bevacizumab, Leucovorin, Oxaliplatin, Fluorouracil
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Neoplasms, Non-small-cell Lung Cancer, Melanoma, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Urothelial Carcinoma, Colorectal Carcinoma, Ovarian Carcinoma
Interventions
PF-07820435, Sasanlimab
Drug · Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
6
States / cities
Sarasota, Florida • Grand Rapids, Michigan • Nashville, Tennessee
Conditions
Colorectal Cancer, Neoplasm Metastasis
Interventions
Phlebotomy
Procedure
Lead sponsor
Immunicon
Industry
Eligibility
18 Years and older
Enrollment
486 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Colorectal Neoplasm
Interventions
Colonoscopy, Endoscopic Ultrasound, Medical Chart Review, Medical Device Usage and Evaluation, Resection
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
22 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Completed No phase listed Observational Accepts healthy volunteers

Cancer Control Following Polypectomy

NCT00591279
Conditions
Colon Cancer
Interventions
Not listed
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1981 – 2017
U.S. locations
1
States / cities
New York, New York
Conditions
Pancreatic Ductal Adenocarcinoma (PDAC), Squamous Cell Carcinoma of Head and Neck, Colorectal Cancer, Gastric Cancer, Ewing Sarcoma, NTSR1 Expressing Solid Tumours, Neuroendocrine Differentiated (NED) Prostate Cancer
Interventions
[225]-FPI-2059, [111In]-FPI-2058
Drug
Lead sponsor
3B Pharmaceuticals GmbH
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
7
States / cities
Birmingham, Alabama • Duarte, California • Newport Beach, California + 4 more
Completed Not applicable Interventional Results available

Improving Informed Consent for Palliative Chemotherapy

NCT02282722
Conditions
Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Unresectable Pancreatic Cancer
Interventions
Investigational informed consent for chemotherapy, Usual, standard-of-care informed consent for chemotherapy
Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
21 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
8
States / cities
San Francisco, California • Boston, Massachusetts • Milford, Massachusetts + 4 more
Conditions
Colorectal Cancer
Interventions
Usual care, Clinic-focused intervention, Clinic- and patient-focused
Behavioral
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
50 Years to 75 Years
Enrollment
5,066 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
3
States / cities
Detroit, Michigan • Albuquerque, New Mexico • Seattle, Washington
Conditions
Colon Cancer, Rectal Cancer
Interventions
CoFactor and 5FU
Drug
Lead sponsor
Mast Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
5
States / cities
La Jolla, California • Sacramento, California • San Diego, California + 2 more
Conditions
Childhood Burkitt Lymphoma, Childhood Central Nervous System Germ Cell Tumor, Childhood Diffuse Large Cell Lymphoma, Childhood Grade III Lymphomatoid Granulomatosis, Childhood Immunoblastic Large Cell Lymphoma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Liver Cancer, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Malignant Germ Cell Tumor, Recurrent Childhood Medulloblastoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Childhood Visual Pathway Glioma, Recurrent Colon Cancer, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Melanoma, Recurrent Nasopharyngeal Cancer, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Recurrent Wilms Tumor and Other Childhood Kidney Tumors, Recurrent/Refractory Childhood Hodgkin Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
irinotecan hydrochloride, oxaliplatin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 21 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Arcadia, California